Report from the 5th cardiovascular outcome trial (CVOT) summit: Cardiovascular Diabetology

O. Schnell, E. Standl, X. Cos, H.J.L. Heerspink, B. Itzhak, N. Lalic, M. Nauck, A. Ceriello

Research output: Contribution to journalArticlepeer-review


The 5th Cardiovascular Outcome Trial (CVOT) Summit was held in Munich on October 24th-25th, 2019. As in previous years, this summit served as a reference meeting for in-depth discussions on the topic of recently completed and presented CVOTs. This year, focus was placed on the CVOTs CAROLINA, CREDENCE, DAPA-HF, REWIND, and PIONEER-6. Trial implications for diabetes management and the impact on new treatment algorithms were highlighted for diabetologists, cardiologists, endocrinologists, nephrologists, and general practitioners. Discussions evolved from CVOTs to additional therapy options for heart failure (ARNI), knowledge gained for the treatment and prevention of heart failure and diabetic kidney disease in populations with and without diabetes, particularly using SGLT-2 inhibitors and GLP-1 receptor agonists. Furthermore, the ever increasing impact of CVOTs and substances tested for primary prevention and primary care was discussed. The 6th Cardiovascular Outcome Trial Summit will be held in Munich on October 29th-30th, 2020 ( © 2020 The Author(s).
Original languageEnglish
JournalCardiovasc. Diabetol.
Issue number1
Publication statusPublished - 2020


  • Cardiovascular risk
  • CVOT
  • Diabetes
  • GLP-1 receptor agonist
  • SGLT-2 inhibitor
  • alpha glucosidase inhibitor
  • atrasentan
  • canagliflozin
  • creatinine
  • dapagliflozin
  • dulaglutide
  • enalapril
  • glimepiride
  • hemoglobin A1c
  • linagliptin
  • metformin
  • sacubitril plus valsartan
  • semaglutide
  • valsartan
  • dipeptidyl peptidase IV inhibitor
  • GLP1R protein, human
  • glucagon like peptide 1 receptor
  • incretin
  • brain ischemia
  • cardiovascular mortality
  • cardiovascular risk
  • clinical outcome
  • creatinine blood level
  • diabetic ketoacidosis
  • diabetic nephropathy
  • disease severity
  • drug efficacy
  • end stage renal disease
  • estimated glomerular filtration rate
  • heart failure with reduced ejection fraction
  • heart infarction
  • heart left ventricle ejection fraction
  • high risk patient
  • human
  • mortality risk
  • non insulin dependent diabetes mellitus
  • primary medical care
  • primary prevention
  • professional knowledge
  • randomized controlled trial (topic)
  • Review
  • risk reduction
  • unstable angina pectoris
  • adverse event
  • cardiovascular disease
  • clinical trial (topic)
  • treatment outcome
  • Cardiovascular Diseases
  • Clinical Trials as Topic
  • Diabetes Mellitus, Type 2
  • Dipeptidyl-Peptidase IV Inhibitors
  • Glucagon-Like Peptide-1 Receptor
  • Humans
  • Incretins
  • Sodium-Glucose Transporter 2 Inhibitors
  • Treatment Outcome


Dive into the research topics of 'Report from the 5th cardiovascular outcome trial (CVOT) summit: Cardiovascular Diabetology'. Together they form a unique fingerprint.

Cite this